Inicio
Resultado de la búsqueda
1 búsqueda de la palabra clave 'Disease free survival'
Clasificado(s) por (Año de edición descendente) Refinar búsqueda Genera el flujo rss de la búsqueda
Enlace permanente de la investigación
Measurable residual disease assessment and allogeneic transplantation as consolidation therapy in adult acute lymphoblastic leukemia in Colombia / Marcos Arango Barrientos ; Laura María Díaz Correa
Título : Measurable residual disease assessment and allogeneic transplantation as consolidation therapy in adult acute lymphoblastic leukemia in Colombia Tipo de documento : documento electrónico Autores : Marcos Arango Barrientos, ; Laura María Díaz Correa, Fecha de publicación : 2020 Títulos uniformes : Clinical Lymphoma, Myeloma & Leukemia Idioma : Inglés (eng) Palabras clave : Acute lymphoblastic leukemia Disease free survival Hematopoietic stem-cell transplantation Measurable residual disease Prognosis Resumen : Introduction: Detectable minimal residual disease (MRD) after therapy for acute lymphoblastic leukemia (ALL) is the strongest predictor of hematologic relapse. The objective of the study was to assess disease-free survival (DFS) and overall survival (OS) of patients with ALL according with MRD status at the end of induction therapy in a Colombian population. Patients and Methods: We assessed a retrospective cohort to compare DFS and OS in adults with de novo ALL according to MRD status at the end of induction chemotherapy, and the type of postinduction consolidation strategy used. Results: A total of 165 adults with ALL were included in the MRD part of the study, 73 patients in the MRD-negative group and 92 in the MRD-positive group. Median DFS for the MRD-positive group was 11 months (95% confidence interval, 11.7-22.2) and was not reached for the MRD-negative group ( P Mención de responsabilidad : Juan Felipe Combariza, Marcos Arango, Laura Díaz, Claudia Agudelo, Sonia Hernandez, Ana María Madera, Guillermo León, Vladimir Avila, Leonardo Bautista, Jaime Valdés, Rocio Orduz, Fabian Mejía, Liliana Moreno y Carlos Ramirez Referencia : Clin Lymphoma Myeloma Leuk. 2021 Apr;21(4):e365-e372. DOI (Digital Object Identifier) : 10.1016/j.clml.2020.11.010 PMID : 33277225 En línea : https://linkinghub.elsevier.com/retrieve/pii/S2152-2650(20)30634-0 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=5187 Measurable residual disease assessment and allogeneic transplantation as consolidation therapy in adult acute lymphoblastic leukemia in Colombia [documento electrónico] / Marcos Arango Barrientos, ; Laura María Díaz Correa, . - 2020.
Obra : Clinical Lymphoma, Myeloma & Leukemia
Idioma : Inglés (eng)
Palabras clave : Acute lymphoblastic leukemia Disease free survival Hematopoietic stem-cell transplantation Measurable residual disease Prognosis Resumen : Introduction: Detectable minimal residual disease (MRD) after therapy for acute lymphoblastic leukemia (ALL) is the strongest predictor of hematologic relapse. The objective of the study was to assess disease-free survival (DFS) and overall survival (OS) of patients with ALL according with MRD status at the end of induction therapy in a Colombian population. Patients and Methods: We assessed a retrospective cohort to compare DFS and OS in adults with de novo ALL according to MRD status at the end of induction chemotherapy, and the type of postinduction consolidation strategy used. Results: A total of 165 adults with ALL were included in the MRD part of the study, 73 patients in the MRD-negative group and 92 in the MRD-positive group. Median DFS for the MRD-positive group was 11 months (95% confidence interval, 11.7-22.2) and was not reached for the MRD-negative group ( P Mención de responsabilidad : Juan Felipe Combariza, Marcos Arango, Laura Díaz, Claudia Agudelo, Sonia Hernandez, Ana María Madera, Guillermo León, Vladimir Avila, Leonardo Bautista, Jaime Valdés, Rocio Orduz, Fabian Mejía, Liliana Moreno y Carlos Ramirez Referencia : Clin Lymphoma Myeloma Leuk. 2021 Apr;21(4):e365-e372. DOI (Digital Object Identifier) : 10.1016/j.clml.2020.11.010 PMID : 33277225 En línea : https://linkinghub.elsevier.com/retrieve/pii/S2152-2650(20)30634-0 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=5187 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD001633 AC-2020-127 Archivo digital Producción Científica Artículos científicos Disponible